Floatz logo

Sorafenib

Fibrolamellar Carcinoma

St. Jude Children's Research HospitalSmall moleculePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

25 Active assets in the Fibrolamellar Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Children's Oncology Group
Phase 3BB
FLUOROURACILUM
M.D. Anderson Cancer Center
Phase 3BB
Nivolumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2B
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Children's Oncology Group
Phase 3B

View all 37 →

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
SorafenibDormant
BBB
Indicative ·
75 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →